Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 22.6169
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 12344651858.0
- FreeCF/Share 0.5326
- PFCF 103.2973
- PE 65.7348
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuation reflects high growth expectations, leaving little room for missteps amid FDA scrutiny of compounded GLP-1 marketing and new tariff uncertainties. I'm expecting Hims & Hers to see near-term volatility followed by a break as uncertainty around tariffs and the FDA settles.
Read More
Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
Published: September 26, 2025 by: Benzinga
Sentiment: Positive
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).
Read More
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Kuehn Law Encourages Investors of Hims & Hers Health, Inc. to Contact Law Firm
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Hims & Hers Health, Inc. (NYSE: HIMS) breached their fiduciary duties to shareholders.
Read More
Hims & Hers Expands Care Ecosystem via Global and Digital Innovation
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS is scaling globally with AI-powered care, new treatments and an $870 million boost to expand its digital ecosystem.
Read More
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 19, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.
Read More
Telehealth Stock Looks Primed for a Short Squeeze
Published: September 19, 2025 by: Schaeffers Research
Sentiment: Positive
Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.
Read More
Hims & Hers Health: Bumpy Ride Will End
Published: September 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scrutiny, but this is industry-wide and not unique to the company. The platform is rapidly growing subscribers, launching new offerings, and targeting large under-penetrated markets domestically and internationally in a path to hitting a $6.5B 2030 sales target.
Read More
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Read More
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
Published: September 15, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.
Read More
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX® , an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, underscoring KYZATREX's position as a leader in the testosterone therapy space.
Read More
Hims & Hers: The Next Chapter For Investors
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Positive
Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.
Read More
Hims & Hers launches treatment plans for low testosterone
Published: September 10, 2025 by: Reuters
Sentiment: Positive
Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.
Read More
Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its digital health footprint with global moves, top-tier partnerships and more than 1,500 providers.
Read More
HIMS' Personalized Wellness Platform Expands Preventive Care Access
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.
Read More
HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands globally, while Amwell leans on federal contracts and software growth. Let's see which has the edge in earnings growth & strategic expansion.
Read More
Hims & Hers Scales Growth Through Subscriptions and Care Expansion
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.
Read More
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Published: August 25, 2025 by: Benzinga
Sentiment: Positive
Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc RKT, Oscar Health Inc OSCR, and Hims & Hers Health Inc HIMS are sitting at the top of the market's short-interest leaderboard, each with more than a quarter of their float sold short.
Read More
HIMS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the August 25th Deadline for the Hims Lawsuit and Urges Investors to Contact The Firm
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options
Read More
DEADLINE ALERT for HIMS, IRBT, and CNC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Hims & Hers: Personalized Care To Sustain Revenue Growth Despite GLP-1 Hiccup
Published: August 22, 2025 by: Seeking Alpha
Sentiment: Positive
I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract with Novo Nordisk, HIMS is adapting quickly, maintaining revenue growth and benefiting from high customer retention and positive feedback. The company's financials show sustained profitability, robust revenue growth, and a premium valuation justified by its superior performance compared to competitors like Teladoc.
Read More
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges that Hims made misleading statements about its GLP-1 weight-loss drug business and its partnership with Novo Nordisk, which was abruptly canceled.
Read More
MONDAY DEADLINE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action by August 25, 2025
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" …
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637